Premium
Characterization of CD34 + hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination
Author(s) -
Mayado A.,
Teodosio C.,
DasilvaFreire N.,
JaraAcevedo M.,
GarciaMontero A. C.,
ÁlvarezTwose I.,
SánchezMuñoz L.,
Matito A.,
Caldas C.,
MuñozGonzález J. I.,
Henriques A.,
SánchezGallego J. I.,
Escribano L.,
Orfao A.
Publication year - 2018
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.13413
Subject(s) - cd34 , systemic mastocytosis , haematopoiesis , myeloid , bone marrow , mutation , immunology , flow cytometry , proto oncogene proteins c kit , biology , stem cell , cancer research , microbiology and biotechnology , stem cell factor , genetics , gene
Background Recent studies show that most systemic mastocytosis (SM) patients, including indolent SM (ISM) with (ISMs+) and without skin lesions (ISMs−), carry the KIT D816V mutation in PB leukocytes. We investigated the potential association between the degree of involvement of BM hematopoiesis by the KIT D816V mutation and the distribution of different maturation‐associated compartments of bone marrow (BM) and peripheral blood (PB) CD34 + hematopoietic precursors (HPC) in ISM and identified the specific PB cell compartments that carry this mutation. Methods The distribution of different maturation‐associated subsets of BM and PB CD34 + HPC from 64 newly diagnosed ( KIT ‐mutated) ISM patients and 14 healthy controls was analyzed by flow cytometry. In 18 patients, distinct FACS‐purified PB cell compartments were also investigated for the KIT mutation. Results ISM patients showed higher percentages of both BM and PB MC‐committed CD34 + HPC vs controls, particularly among ISM cases with MC‐restricted KIT mutation (ISM MC ); this was associated with progressive blockade of maturation of CD34 + HPC to the neutrophil lineage from ISM MC to multilineage KIT ‐mutated cases (ISM ML ). Regarding the frequency of KIT ‐mutated cases and cell populations in PB, variable patterns were observed, the percentage of KIT ‐mutated PB CD34 + HPC, eosinophils, neutrophils, monocytes and T cells increasing from ISMs− MC and ISMs+ MC to ISM ML patients. Conclusion The presence of the KIT D816V mutation in PB of ISM patients is associated with (early) involvement of circulating CD34 + HPC and multiple myeloid cell subpopulations, KIT ‐mutated PB CD34 + HPC potentially contributing to early dissemination of the disease.